Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TP-1287 |
Synonyms | |
Therapy Description |
TP-1287 is a prodrug of the CDK9 inhibitor Alvocidib with improved oral availability, resulting in enhanced tumor cell toxicity (Cancer Res 2017;77(13 Suppl):Abstract nr 5133). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TP-1287 | TP1287|TP 1287 | TP-1287 is a prodrug of the CDK9 inhibitor Alvocidib with improved oral availability, resulting in enhanced tumor cell toxicity (Cancer Res 2017;77(13 Suppl):Abstract nr 5133). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03604783 | Phase I | TP-1287 | Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |